Concepedia

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Myron S. Czuczman, Aron D. Thall, Thomas E. Witzig, Julie M. Vose, Anas Younes, Christos Emmanouilides, Thomas P. Miller, Joseph O. Moore, John P. Leonard, Leo I. Gordon,

Journal of Clinical Oncology · 2005 · 148 citations · 11 references

DOIFull text

Open access

Abstract

The favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.

References

11

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Rituximab: Mechanism of action and resistance

David G. Maloney, Barbara Smith, Andrea L. Rose · Seminars in Oncology · 2002 · 368 citations

, , +5

Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma

Susmit Suvas, Vinod Singh, Sudhir Sahdev et al. · Journal of Biological Chemistry · 2002 · 237 citations · Full text

, , +16

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma

Gary H. Lyman, David J. Delgado · Cancer · 2003 · 196 citations

Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma

Y Bastion, Pauline Brice, Corinne Haïoun et al. · Blood · 1995 · 179 citations · Full text